Abstract | PURPOSE: DESIGN: Prospective, noncomparative case series. METHODS: The authors report the clinical characteristics and outcomes of patients who entered this multicentered, open-label, clinical trial. Eighty-three patients with Acanthamoeba keratitis representing 87 infected eyes entered the trial. RESULTS: Sixty (69%) of the 87 eyes enrolled had data analyzed for treatment efficacy and safety. Of these 60 eyes, 50 (83%) experienced treatment success. Thirty (60%) patients successfully treated adhered to treatment protocol guidelines. Patients who broke protocol had disease exacerbation during the maintenance therapy phase. The only eyes lost/enucleated were 7 of 17 in which penetrating keratoplasty was performed before eradication of the infectious agent. CONCLUSION:
|
Authors | S L Hargrave, J P McCulley, Z Husseini |
Journal | Ophthalmology
(Ophthalmology)
Vol. 106
Issue 5
Pg. 952-7
(May 1999)
ISSN: 0161-6420 [Print] United States |
PMID | 10328395
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Benzamidines
- Ophthalmic Solutions
- propamidine isethionate
- Neomycin
|
Topics |
- Acanthamoeba Keratitis
(drug therapy, etiology, surgery)
- Adolescent
- Adult
- Aged
- Anti-Bacterial Agents
(therapeutic use)
- Antiprotozoal Agents
(therapeutic use)
- Benzamidines
(therapeutic use)
- Contact Lenses
(adverse effects)
- Drug Therapy, Combination
- Eye Enucleation
- Female
- Humans
- Keratoplasty, Penetrating
- Male
- Middle Aged
- Neomycin
(therapeutic use)
- Ophthalmic Solutions
(therapeutic use)
- Prospective Studies
- Safety
- Treatment Outcome
|